Skip to main content

Table 1 Baseline characteristics of survey participants (N = 124)

From: Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment

Characteristics %
Age, years
 18–29 2
 30–44 30
 45–60 64
  > 60 5
Sex
 Male 75
 Female 25
Year HCV diagnosis was received
 Before 1999 40
 1999–2003 15
 2004–2008 18
 2009–2013 13
 2014–2018 15
Comorbidities (more than one could be selected)
 HBV 13
 HIV 24
 Cardiovascular disease 7
 Diabetes 2
 Other 13
Currently injecting drugs
  ≥ once a week 17
  < once a week 17
 No longer injecting 66
Use of opioids/stimulants at start of HCV treatment
 Users 65
 Non-users 34
 Did not remember 1
Substances used
 Opioids (e.g. heroin, morphine) 92
 Stimulants (e.g. cocaine, amphetatmine) 85
 Both opioids and stimulants 78
 Other substances 58
Country
 UK 16
 Germany 16
 France 16
 Italy 16
 Spain 16
 Portugal 12
 Switzerland 7
Recruitment channel
 Patient association/organisation 62
 HCP referral 20
 Recruiter panel 13
 Patient referral 3
 Online campaign 2
Year started most recent HCV treatment
  ≥ 5 years ago 8
 4 years ago 5
 3 years ago 10
 2 years ago 19
 1 year ago 33
 This year 26
Where most recent HCV treatment was received
 Secondary care/hospital 73
 Addiction clinic 14
 GP/PCP 5
 Prison 2
 Other 3
HCV treatment most recently receiveda (more than one could be selected)
 SOF/VEL 27
 LDV/SOF 23
 SOF 14
 GLE/PIB 6
 DCV 5
 EBR/GZR 2
 TEL 2
 SOF/VEL/VOX 2
 OBV/PTV/r 2
 DSV 2
 BOC 2
 Other/unknown 23
  1. aThe treatment regimen received by participants was at the discretion of their treating physician and was a function of the timing of the research, and/or regulatory approvals and reimbursement in each country
  2. BOC Boceprevir, DCV Daclatasvir, DSV Dasabuvir, EBR Elbasvir, GLE Glecaprevir, GP General practitioner, GZR Grazoprevir, HBV Hepatitis B virus, HCP Healthcare professional, HCV Hepatitis C virus, HIV Human immodeficiency virus, LDV Ledipasvir, OBV Ombitasvir, PCP Primary care physician, PIB Pibrentasvir, PTV Paritaprevir, r Ritonavir, SOF Sofosbuvir, TEL Telaprevir, VEL Velpatasvir, VOX Voxilaprevir